How many patents does
Csl have?
patents
901
families
103
granted
188
applications
713
US
179
EP
143
WO
56
JP
55
CN
54
KR
39
GB
12
RoW
363
Buy the report
The report contains ten-year analysis with the following sections
- patent filing analysis
- worldwide filing analysis
- patent family analysis
- application analysis
- granted analysis
- classification analysis
- citation analysis
contact us for pricing
- VAT will apply to UK companies
- EU companies must supply their VAT number
Check out our sample pages |
Find companies to compare
Many companies now available
companies
12,000+
patents
42 million
patent families
23 million
Search to find companies of interest
read summary of their published patent
the following tables are just extracts from the report
the company report contains more information
Csl
Top ten assignees appearing on patents
2009 - 2018
| csl | 705 |
| csl behring | 54 |
| b-creative sweden | 27 |
| pfizer | 18 |
| merck & company | 13 |
| csl behring recombinant facility | 11 |
| coley pharmaceutical group | 9 |
| csl (dualcom) | 4 |
| cls | 3 |
| walter & eliza hall inst of medica… 🛈 | 2 |
2018
| csl | 66 |
| csl behring | 10 |
| csl behring recombinant facility | 9 |
| b-creative sweden | 5 |
Csl
The top ten patent families are
|
Title of patent family (most common patent title) |
Family members |
Filing year |
|---|---|---|
| a reconstituted high density lipoprotein formulation and production method thereof | 29 | 2010 |
| high affinity antibody antagonists of interleukin-13 receptor alpha 1 | 28 | 2006 |
| humanized anti-interleukin 3 receptor alpha chain antibodies | 27 | 2010 |
| porphorymonas gingivalis polypeptides and polynucleotides | 25 | 1997 |
| reconstituted hdl formulation | 25 | 2012 |
| inhibitory anti-factor xii/xiia monoclonal antibodies and their uses | 25 | 2011 |
| antibodies against g-csfr and uses thereof | 24 | 2011 |
| immunogenic lhrh compositions and methods relating thereto | 23 | 1997 |
| process for preparing apolipoprotein a-i (apo a-i) | 22 | 2013 |
| dosage regime for apolipoprotein formulations | 22 | 2011 |